EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Messenger RNA Therapy for Female Reproductive Health

Rachel VanKeulen-Miller, Owen S Fenton iD

Molecular Pharmaceutics · 05.02.2024 · 21 (2) · 393-409

DOI: 10.1021/acs.molpharmaceut.3c00803 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 08.01.2024. Verfasst von Rachel VanKeulen-Miller und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States. Hauptthemen laut MEDLINE: Reproductive Health, Sexually Transmitted Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 178 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, U.S. Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Female reproductive health has traditionally been an underrepresented area of research in the drug delivery sciences. This disparity is also seen in the emerging field of mRNA therapeutics, a class of medicines that promises to treat and prevent disease by upregulating protein expression in the body. Here, we review advances in mRNA therapies through the lens of improving female reproductive health. Specifically, we begin our review by discussing the fundamental structure and biochemical modifications associated with mRNA-based drugs. Then, we discuss various packaging technologies, including lipid nanoparticles, that can be utilized to protect and transport mRNA drugs to target cells in the body. Last, we conclude our review by discussing the usage of mRNA therapy for addressing pregnancy-related health and vaccination against sexually transmitted diseases in women. Of note, we also highlight relevant clinical trials using mRNA for female reproductive health while also providing their corresponding National Clinical Trial identifiers. In undertaking this review, our aim is to provide a fundamental background understanding of mRNA therapy and its usage to specifically address female health issues with an overarching goal of providing information toward addressing gender disparity in certain aspects of health research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reproductive HealthSexually Transmitted DiseasesPregnancyHumansFemaleRNA, Messenger

Stichwörter der Autor:innen

female healthlipid nanoparticlesmRNA therapiespregnancysexually transmitted infections

Substanzen

RNA, Messenger

Autor:innen und Institutionen

  • Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
  • Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

ORCID-Profile: Owen S Fenton

Förderung

  • NCATS NIH HHS
  • U.S. Department of Health and Human Services

Zitieren

APA

VanKeulen-Miller, R., & Fenton, O. S. (2024). Messenger RNA Therapy for Female Reproductive Health. Molecular Pharmaceutics, 21(2), 393-409. https://doi.org/10.1021/acs.molpharmaceut.3c00803

Vancouver

VanKeulen-Miller R, Fenton OS. Messenger RNA Therapy for Female Reproductive Health. Molecular Pharmaceutics. 2024;21(2):393-409. doi:10.1021/acs.molpharmaceut.3c00803

BibTeX
@article{VanKeulenMiller2024,
  author = {VanKeulen-Miller, Rachel and Fenton, Owen S},
  title = {Messenger RNA Therapy for Female Reproductive Health},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {2},
  pages = {393--409},
  doi = {10.1021/acs.molpharmaceut.3c00803}
}
Kostenlos starten →